Trial Profile
AcSe CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anaplastic large cell lymphoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Liver cancer; Muscle tissue neoplasms; Neuroblastoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours; Thyroid cancer
- Focus Therapeutic Use
- Acronyms AcSe; AcSe-CRIZOTINIB
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 06 Dec 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 05 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Jan 2023.